Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans (IMAGE)

PLOS

Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans

Caption

The impact of tecovirimat on the time to mpox clearance is predicted by a mathematical modeling framework combining pre-clinical and clinical data on mpox dynamics and tecovirimat antiviral activity. Created with Biorender.com.

Credit

Team BIPID, Université Paris Cité (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Usage Restrictions

Credit must be given to the creator.

License

CC BY

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.